01

Dec 2017

Product News

Aurobindo Receives FDA Approval for Quetiapine Fumarate Extended Release Tablets.

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300mg and 400mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Quetiapine Fumarate Extended-Release Tablets 50 mg, 150 mg, 200 mg, 300 mg, and 400

[...] Read more
30

Oct 2017

Industry News

Aurobindo wins Company of the Year, Asia-Pacific Award at the Global Generics & Biosimilars Awards 2017

Frankfurt, 24 October 2017 – Aurobindo Pharma Limited and Generics Bulletin are pleased to announce that Aurobindo has won the Company of the Year, Asia-Pacific Award at the Global Generics & Biosimilars Awards 2017, organized by Generics Bulletin. The Company of the Year, Asia-Pacific Award was sponsored by Eva Pharma and judged by an expert panel. “Congratulations

[...] Read more
30

Oct 2017

Product News

Aurobindo Receives FDA Approval for Prasugrel Tablets, 5 mg and 10mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Prasugrel Tablets, 5 mg and 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Prasugrel Tablets, 5 mg and 10 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Effient®

[...] Read more
11

Oct 2017

Product News

Aurobindo Receives FDA Approval for Ezetimibe Tablets USP, 10 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ezetimibe Tablets USP, 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Ezetimibe Tablets USP, 10 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug ZETIA®. Ezetimibe is indicated as

[...] Read more
11

Oct 2017

Product News

Aurobindo Receives FDA Approval for Moxifloxacin Ophthalmic Soln. 0.5%.

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Moxifloxacin Ophthalmic Soln. 0.5%. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Moxifloxacin Ophthalmic Soln. 0.5%. to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Vigamox® Moxifloxacin Ophthalmic Solution is indicated as

[...] Read more